Verubecestat companion diagnostic - Luminex/Merck
Latest Information Update: 15 Mar 2013
At a glance
- Originator Luminex Corporation; Merck & Co
- Developer Luminex Corporation
- Class Diagnostic agents; Protein diagnostics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Alzheimer's disease
Most Recent Events
- 13 Mar 2013 Clinical trials in Alzheimer's disease (diagnosis) in USA (unspecified route)